Azitra Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Azitra Inc. - overview
Established
2014
Location
Branford, CT, US
Primary Industry
Biotechnology
About
Azitra Inc. is a U. S. -based biotechnology company focused on precision dermatology, developing innovative therapeutics for adverse skin conditions through engineered live biotherapeutics and therapeutic proteins.
Founded in 2014 in Branford, US, Azitra Inc. specializes in developing dermatological therapeutics. The company’s latest funding round was a PIPE in June 2023, raising USD 20. 00 mn from Alumni Capital Network, bringing the total amount raised to USD 20.
00 mn. The CEO is Francisco Salva, and the founder is Isabelle Lecoutre. Azitra specializes in precision dermatology through the development of innovative therapeutics for treating adverse skin conditions. Its core products include engineered live biotherapeutic products and therapeutic proteins aimed at diseases like Netherton syndrome and ichthyosis vulgaris.
Key candidates in their product pipeline include ATR-12, targeted at Netherton syndrome; ATR-04 for EGFR inhibitor-associated rashes; and ATR-01 for ichthyosis vulgaris, primarily aimed at dermatology clinics and healthcare providers in North America and Europe. Azitra generated revenue of USD 7,500 in 2024, with an EBITDA of USD -10,536,905. The company’s revenue model is based on B2B partnerships with healthcare providers and pharmaceutical companies, alongside potential revenue from grants for R&D initiatives, with a focus on tiered pricing strategies and licensing agreements. In June 2023, Azitra Inc.
completed an IPO, raising USD 7. 50 mn by selling 1. 5 million shares at USD 5 per share, which will be used for clinical trials, product development, and general corporate purposes. The company plans to launch new products targeting skin conditions and expand its market presence in North America and Europe by the end of 2024.
Current Investors
Breakout Ventures, Bios Partners, Connecticut Innovations
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Aesthetic Medicine, Dermatology, Pharmaceutical Research & Development
Website
www.azitrainc.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Azitra Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Announced | Azitra Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.